# Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

> **NCT03213626** · PHASE2 · TERMINATED · sponsor: **Patrick Joseph Loehrer Sr.** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** Cabozantinib 40 MG
- **DRUG:** Erlotinib 100Mg Tab

## Key facts

- **NCT ID:** NCT03213626
- **Lead sponsor:** Patrick Joseph Loehrer Sr.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-13
- **Primary completion:** 2019-04-15
- **Final completion:** 2019-11-18
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** There were no objective responses by patient 7.
- **Last updated:** 2020-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213626, "Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03213626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*